Kavar Capital Partners LLC Has $1.53 Million Position in Novo Nordisk A/S (NYSE:NVO)

Kavar Capital Partners LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 16.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,012 shares of the company’s stock after purchasing an additional 4,213 shares during the period. Kavar Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $1,532,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fisher Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 2.2% during the 2nd quarter. Fisher Asset Management LLC now owns 14,901,234 shares of the company’s stock valued at $760,559,000 after purchasing an additional 321,562 shares in the last quarter. Northern Trust Corp boosted its position in shares of Novo Nordisk A/S by 0.5% during the 1st quarter. Northern Trust Corp now owns 2,330,848 shares of the company’s stock valued at $121,926,000 after purchasing an additional 11,457 shares in the last quarter. Boston Partners boosted its position in shares of Novo Nordisk A/S by 4.0% during the 1st quarter. Boston Partners now owns 2,257,710 shares of the company’s stock valued at $118,101,000 after purchasing an additional 87,878 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in Novo Nordisk A/S by 2.2% during the 1st quarter. Parametric Portfolio Associates LLC now owns 2,005,391 shares of the company’s stock worth $104,902,000 after buying an additional 42,519 shares during the period. Finally, Saratoga Research & Investment Management raised its stake in Novo Nordisk A/S by 2.6% during the 2nd quarter. Saratoga Research & Investment Management now owns 1,549,469 shares of the company’s stock worth $79,085,000 after buying an additional 39,123 shares during the period. 7.16% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently weighed in on NVO. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday, August 5th. Deutsche Bank downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price target on the stock. in a research note on Thursday, June 20th. UBS Group reaffirmed a “buy” rating and set a $355.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, June 19th. Credit Suisse Group raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. Finally, Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price target on the stock in a research note on Monday, July 15th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $111.58.

NVO stock traded up $0.73 during trading on Thursday, reaching $51.06. 78,501 shares of the stock were exchanged, compared to its average volume of 1,655,609. The business’s 50 day simple moving average is $49.52. Novo Nordisk A/S has a twelve month low of $41.23 and a twelve month high of $52.83. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $124.01 billion, a price-to-earnings ratio of 20.23, a P/E/G ratio of 2.15 and a beta of 0.60.

The company also recently declared a Semi-Annual dividend, which will be paid on Tuesday, August 27th. Investors of record on Monday, August 19th will be paid a dividend of $0.318 per share. The ex-dividend date of this dividend is Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 44.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: What does it mean to hold a stock in street name?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.